Dr Katrina Green
|Phone:||+61 2 4252 8506|
- Lecturer in School of Medicine
- Affiliated Research Scientist, Illawarra Health and Medical Research Institute
- Affiliated Research Scientist, Schizophrenia Research Institute
Teaching and Coordinating:
- Undergraduate medical science subjects
- SHS112: Introduction to Anatomy and Physiology II (subject coordinator and lecturer)
- SHS211: Control Mechanisms Physiology (subject coordinator and lecturer)
- Research supervision
Katrina has a PhD in neuroscience/neuroendocrinology and completed a post-doctoral fellowship in the Antipsychotics Research Laboratory at the Illawarra Health and Medical Research Institute.
Background: Antipsychotic drugs are prescribed to treat schizophrenia, bipolar disorder and a growing number of other mental disorders in adults and children. Unfortunately, antipsychotics are often unable to treat all symptoms of these illnesses, and can cause serious side-effects, such as obesity and type 2 diabetes, by unclear mechanisms. These metabolic side-effects can have a devastating impact on quality of life and expose people to further serious health complications such as cardiovascular disease and stroke.
Katrina’s research aims to improve the lives of people living with chronic mental illness by investigating novel adjunct pharmacotherapies that can increase treatment efficacy and prevent the obesity and type 2 diabetes side-effects associated with popular antipsychotic drugs. Katrina's research targets the neuroendocrine systems of the body and she has a special interest in the therapeutic benefits of incretin hormones and their analogues.
Katrina is also actively interested in the Learning-Teaching-Research nexus.
To discuss your interest in an undergraduate honours or post-graduate research project in this field, please contact Dr Green or the Faculty student services at: email@example.com
Searchable RIS publications from 2006 to date
- Weston-Green K, Huang XF, and Deng C (2013). Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor. CNS Drugs, 27(12):1069-1080.
- Weston-Green K, Huang X-F, Deng C (2012). Alterations to Melanocortinergic, GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine-Induced Weight Gain. PLoS ONE, 7(3): e33548 – March 16, 2012
- Weston-Green K, Huang XF, Lian J, Deng C (2012). Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. European Neuropsychopharmacology. 22(5): 364-373
- Weston-Green K, Huang X-F, Deng C (2011). Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behavioural Brain Research. 217(2): 337-346
- Weston-Green K, Huang X-F, Deng C (2010). Sensitivity of the female rat to olanzapine-induced weight gain--Far from the clinic? Schizophrenia Research 116(2-3): 299-300
- Deng C, Weston-Green K, Huang X-F (2010). The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain? Progress in Neuropsychopharmacology and Biological Psychiatry 34(1): 1-4
- Weston-Green K, Huang X-F, Han M, Deng C (2008). The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain. The International Journal of Neuropsychopharmacology 11(06): 827-835
- Deng C, Weston-Green KL, Han M, Huang X-F (2007). Olanzapine treatment decreases the density of muscarinic M2 receptors in the dorsal vagal complex of rats. Progress in Neuropsychopharmacology and Biological Psychiatry 31(4): 915-920